Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01459666
Other study ID # CASE1Z12
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date September 2011
Est. completion date August 2019

Study information

Verified date April 2022
Source University Hospitals Cleveland Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox. Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.


Description:

Primary Objective: -To evaluate the efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) at 6 weeks post surgery. Secondary Objectives: - To evaluate efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Patient and Observer Assessment Scale (POSAS) at week 1, 6, and 24. - To evaluate the efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) at week 1 and 24 post surgery. - To evaluate patient satisfaction - To evaluate safety (adverse events) This is a 6 month, prospective, multicenter, double-blinded, randomized, placebo-controlled study. A total of 40 male or female healthy volunteers, 20 in each arm, will be enrolled. Up to 10 more patients can be enrolled to account for patient drop-out. Subjects will all undergo Mohs micrographic surgical removal of a skin cancer lesion on the forehead followed by reconstruction. Subjects will be randomized to receive either aboBTX-A injection or placebo injection in the frontalis, procerus, and corrugator muscles prior to reconstruction. Photographs, POSAS, and clinical assessments will be taken immediately after initial wound closure, at 1 week follow-up, at 6 weeks follow-up, and at 6 months follow-up. Adverse events will also be reviewed at each study visit. After the completion of the study, the photographs will be assessed (blinded as to the patient identifiers) using a 10 cm visual analog scale (VAS). The first few photographs will be evaluated by the surgeons together to calibrate the VAS and ensure inter-reliability.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date August 2019
Est. primary completion date August 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for enrollment: - Ability to understand the risks, benefits, and alternative to participation and give informed consent - Have biopsy proven skin cancer on the medial forehead that is amenable to Mohs surgery. Medial forehead is defined as the area superiorly from the hairline, inferiorly at the eyebrow, and laterally to the tip of the lateral brow (see diagram). - Undergoing elective reconstruction of biopsy proven skin cancer that is amenable to Mohs surgery with defect size measuring 1.0 cm or greater - If female, not currently pregnant, no potential for pregnancy, or if of child-bearing age, must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for 30 days after the last dose of study drug. A negative urine pregnancy test is required at study entry for female subjects of childbearing potential: a woman is considered to be of child bearing potential unless she has had a tubal ligation, total hysterectomy, bilateral oopherectomy, or is postmenopausal (without a menstrual period for at least one year) - Agrees to not use disallowed concomitant medications (retinoids) Exclusion Criteria: The presence of any of the following will exclude a patient from study enrollment. - Pregnant women, women who are breastfeeding, or women of child bearing age who are unwilling to use adequate contraception (described above) during the study period - Current or past history of a neuromuscular disease (such as myasthenia gravis, amyotrophic lateral sclerosis, Eaton-Lambert syndrome) - Currently taking aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) - History of radiation therapy or chemotherapy - History of keloid or other hypertrophic scar formation - Current or past history of scleroderma - Has used botulinum toxin in the forehead area within one year. - Has significant resting eyebrow ptosis - Has used any topical retinoids to the forehead area within the past 4 weeks - Undergo any scar revision procedure for the duration of the study including intralesional kenalog, laser treatment, and/or scar revision surgeries - Any hypersensitivity to any component of abobotulinumtoxinA (i.e. cow milk protein) or any previous hypersensitivity to any botulinum toxin A or related product. - Non-English speaking: These patients are excluded since translation of the informed consent into other languages is time-consuming and expensive as it requires a bona fide translator for the particular language of interest and this type of person may be difficult to locate. - House staff and students, medical students on a clerkship, and employees related to study personnel or who work for any study personnel, and members of the study team are not eligible to participate in this study as a subject. - The investigator feels that for any reason the subject is not eligible to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dysport (abobotulinumtoxinA)
Intramuscular injection effects lasting up to 3 months
Bacteriostatic 0.9% Sodium Chloride (vehicle)
Intramuscular injection

Locations

Country Name City State
United States University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio
United States UH Cleveland Medical Center-Westlake Westlake Ohio

Sponsors (1)

Lead Sponsor Collaborator
University Hospitals Cleveland Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Scale (VAS) It consists of a 10 point scale to assess global scar assessment. Scar photographic images are assessed by independent physicians, and previous studies have shown very high intrarater consistency. 6 weeks post surgery
Secondary Patient and Observer Assessment Scale (POSAS) The Patient and Observer Scar Assessment Scale (POSAS) consists of two numeric scales. One scale is completed by the patients, the other by the clinician. This scale is different than previous scales because it takes the patient's input into consideration. It has good internal consistency and interobserver reliability. The assessment will take place at Day 0, Week 1, Week 6, and Month 6. at week 1, 6, and 24 post surgery
Secondary Visual Analogue Scale (VAS) Evaluate efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) at week 1 and 24 post surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT01706848 - Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound N/A
Recruiting NCT01177358 - Botox in the Healing of Surgical Wounds of the Neck Phase 2
Completed NCT00970671 - Treatment of Surgical Scars Using the Pulsed Dye Laser N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Completed NCT05293652 - Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar N/A
Recruiting NCT03406143 - Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration N/A
Completed NCT05527756 - Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery
Completed NCT02886988 - Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection Phase 2/Phase 3
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Recruiting NCT05408117 - Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color N/A
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Terminated NCT02520557 - An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
Not yet recruiting NCT04621994 - Cesarean Wound Closure: Dermabond Versus Steri Strips N/A
Withdrawn NCT03395678 - Acne Scarring in Skin of Color: Laser vs Microneedling N/A
Completed NCT02744950 - Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs N/A
Not yet recruiting NCT01005992 - Fractional Photothermolysis for the Treatment of Burn Scars Phase 1
Completed NCT04870008 - Aesthetic Outcome of Running Cuticular Suture Distance (2mm vs 5mm) N/A
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A
Recruiting NCT06386549 - Effect of a Tele-rehabilitation Programme in Children With Burns: a Randomized Controlled Trial N/A